Loading
MLLT1 (MLLT1 super elongation complex subunit) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Wilms tumour and 1 more.
Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. Specifically recognises and binds acetylated and crotonylated histones, with a preference for histones that are crotonylated. Has a slightly higher affinity for binding histone H3 crotonylated at 'Lys-27' (H3K27cr) than 'Lys-20' (H3K9cr20).
Open Targets scores its association with cancer at 0.56 (direct and indirect evidence; datatypes literature 0.87, genetic association 0.14, somatic mutation 0.71). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Wilms' Tumour.
In plain words · MLLT1 (MLLT1 super elongation complex subunit) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Wilms tumour and 1 more.
MLLT1 (MLLT1 super elongation complex subunit) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Wilms tumour and 1 more.
Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA.
No product in this corpus aims at MLLT1 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
First described 1992. Earliest sequence paper UniProt cites for the protein: Tkachuk D.C. et al, Cell, 1992, "Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias". Source.
Sources: HGNC HGNC:7134 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q03111 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000130382 (association with cancer (MONDO_0004992) 0.56; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.53, non-Hodgkin lymphoma 0.54, leukaemia 0.56 (GraphQL API, CC0)); IntOGen MLLT1 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. Specifically recognises and binds acetylated and crotonylated histones, with a preference for histones that are crotonylated. Has a slightly higher affinity for binding histone H3 crotonylated at 'Lys-27' (H3K27cr) than 'Lys-20' (H3K9cr20). May play a role in leukemogenic gene transcription. Acts as a key chromatin reader in acute myeloid leukaemia by recognising and binding to acetylated histones via its YEATS domain, thereby regulating oncogenic gene transcription. Location: Nucleus (UniProt). Locus 19p13.3 (HGNC).
Query for this target: (TITLE:"MLLT1" OR ABSTRACT:"MLLT1" OR TITLE:"MLLT1 super elongation complex subunit" OR ABSTRACT:"MLLT1 super elongation complex subunit" OR TITLE:"LTG19" OR ABSTRACT:"LTG19" OR TITLE:"YEATS1" OR ABSTRACT:"YEATS1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MLLT1, not a curated reading list.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.